

Claims

1. A method for the treatment or prophylaxis of disorders in which the overproduction of s-CD23 is implicated, which method comprises the administration of an effective amount of an inhibitor of the formation of human soluble CD23 to a human or non-human mammal in need thereof, with the provisos that:
 - (a) the disorder is not mediated by a matrix metalloprotease or by tissue necrosis factor; and
 - (b) the inhibitor does not form part of the state of the art by virtue of WO92/16517 or WO93/18173.
2. The method according to Claim 1, wherein the inhibitor of the formation of s-CD23 is an inhibitor of matrix metalloprotease.
3. The method according to Claim 1, wherein the inhibitor of the formation of s-CD23 is a hydroxamic acid derivative, a phosphate or a thiol.
4. The method according to Claim 1, wherein the inhibitor of the formation of s-CD23 is selected from:
 - [4-(N-hydroxyamino)-2-(R)-isobutyl-3-(S)-(2-thiophenethiomethyl)succinyl]-(S)-phenylalanine-N-methylamide;
 - N²-[(R)-[hydroxycarbamoylmethyl]-4-methylvaleryl]-N¹, 3-dimethyl-(S)-valinamide;
 - N-[3-(N'-hydroxycarboxamido)-2-(2-methylpropyl)propanoyl]-(S)-O-methyl-L-tyrosine-N-methylamide;
 - methyl 3-(S)-mercapto-6-methyl-4-(S)-[[[1(S)-[(methylamino)carbonyl]-2-(3-indolyl)ethyl]amino]carbonyl]heptanoate;
 - isopropyl 3-(S)-mercapto-6-methyl-4-(S)-[[[1(S)-[(methylamino)carbonyl]-2-(3-indolyl)ethyl]amino]carbonyl]heptanoate;
 - 3-(S)-mercapto-N¹-[1-(S)-[(methylamino)carbonyl]-2-(4-methoxyphenyl)ethyl]-2-(S)-(2-methylpropyl)pentanediamide;
 - N-[N-((S)-1-phosphonopropyl)-(S)-leucyl]-O-methyl-(S)-tyrosine N-methylamide;
 - N-[3-(hydroxycarboxamido)-2R-(2-methylpropyl)propanoyl]-(S)-phenylalanine-N-methylamide; and
 - N-[3-(hydroxycarboxamido)-2R-(2-methylpropyl)propanoyl]-(S)-phenylalanine-N-benzylamide; or
 - a pharmaceutically acceptable salts thereof.

5. The method according to Claim 1, wherein the inhibitor is hereinbefore described with reference to the Table.

5

2009-01-01 10:00:00